- Company
- MSD virtually prohibits one-on-one product presentations
- by Apr 27, 2021 06:04am
- MSD Korea has proposed new rules for one-on-one product presentations with doctors. Product presentations that are not for business purposes are minimized, and the limit for meals is lowered from &8361;100,000 per person to a maximum of &8361;70,000. It is expected that the labor-management conflict will intensify as a counter-argument has
- Company
- Hankook Korus Pharm is preparing for Sputnik V
- by Kim, Jin-Gu Apr 26, 2021 05:51am
- Hankook Korus Pharm announced on the 23rd that it has begun preliminary work for domestic approval of Sputnik V, COVID-19 vaccine developed by Russia. According to Hankook Korus Pharm, the company has recently requested documents related to the permit from the Russian Direct Investment Fund (RDIF) and is preparing the necessary materials f
- Company
- Ninlaro can be prescribed at general hospitals
- by Eo, Yun-Ho Apr 26, 2021 01:34am
- Ninlaro, an oral multiple myeloma treatment that solves the problem of insurance benefits, is prescribed at general hospitals. According to related industries, Ninlaro (Ixazomib), an oral medication option in the field of multiple myeloma (MM), is used in Korea, including Samsung Medical Center, Seoul National University Hospital, the Cath
- Company
- The market share of Hanmi & Chong Kun Dang's is 16%
- by Kim, Jin-Gu Apr 26, 2021 01:29am
- Competition for the generic drug Betmiga (Mirabegron), an overactive bladder treatment, is intensifying in the outpatient prescription market. According to the drug market research agency UBIST on the 20th, the Mirabegron market scale in the first quarter reached &8361;18.3 billion. It increased by 9% compared to &8361;16.7 billion in th
- Company
- Domestic drug Rosuzet/K-CAB sales performance is very good
- by An, Kyung-Jin Apr 26, 2021 01:28am
- Lipitor, a treatment for hyperlipidemia, kept the lead in outpatient prescription sales. Drugs developed with domestic technology such as Rosuzet and Zemiglo, led by HK inno.N's K-CAB, increased sales despite prolonged COVID-19. Original drugs are on a decreasing trend after patent expiration. According to UBIST, a drug research institute on
- Company
- Big 5 Hospitals actively prepare CAR-T ‘Kymria' centers
- by Eo, Yun-Ho Apr 22, 2021 05:53am
- The ‘Big-5’ tertiary hospitals in Korea are working fast to introduce the first CAR-T therapy ‘Kymriah’ to their institutions. According to industry officials, among the Big-5s, Seoul National University Hospital (SNUH), Asan Medical Center (AMC), Seoul St. Mary’s Hospital, and Severance Hospital are in the process of acquiring the
- Company
- Tremfya reimbursement approved for palmoplantar pustulosis
- by Apr 22, 2021 05:53am
- Janssen’s interlukin-23 (IL-23) inhibitor ‘Tremfya (guselkumab)’ will be reimbursed from May 1st for the treatment of palmoplantar pustulosis. The reimbursement will apply to patients over the age of 18 years who were diagnosed with moderate to severe palmoplantar pustulosis that has lasted for more than 6 months that ▲ have a Palmo
- Company
- Sanofi to sell Hanmi's AmosartanQ' in Russia
- by An, Kyung-Jin Apr 22, 2021 05:53am
- Hanmi's IMD AmosartanQ will be launched in the Russian market through Sanofi. Hanmi announced on the 20th that Sanofi has obtained marketing approval from the MOH for AmosartanQ under the product name Tristanium. AmosartanQ is a combination drug that combines Amlodipine Camsylate, a component for treating hypertension of CCB, and Losart
- Company
- Schingles is expected to be released in the end of the year
- by Apr 21, 2021 05:50am
- GSK's Schingles, which boasts the highest efficacy among the existing shingles vaccines, is expected to receive product approval at the end of the year as soon as possible. When Schingles is released in Korea, fierce competition is expected with Zostavax and Sky Zoster. According to the pharmaceutical industry on the 21st, GSK applied for
- Company
- Lynparza tablet to be prescribed at Big 5 hospitals
- by Eo, Yun-Ho Apr 21, 2021 05:49am
- The tablet formulation of the anticancer drug ‘Lynparza’ can now be prescribed at the Big-5 tertiary hospitals. Industry sources reported that AstraZeneca’s poly ADP ribose polymerase (PARP) inhibitor Lynparza (olaparib) passed the review of drug committees (DC) in the five major hospitals, the ‘Big-5s,’ which include the Samsung
